Home › Research › Biomarkers
Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease
Adamczuk K, Schaeverbeke J, Vanderstichele HM, Lilja J, Nelissen N, Van Laere K, Dupont P, Hilven K et al.. Alzheimer's research & therapy, 2015-12-18
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction In this study of preclinical Alzheimer's disease (AD) we assessed the added diagnostic value of using cerebrospinal fluid (CSF) Aβ ratios rather than Aβ42 in isolation for detecting individuals who are positive on amyloid positron emission tomography (PET). Methods Thirty-eight community-recruited cognitively intact older adults (mean age 73, range 65-80 years) underwent (18)F-flutemetamol PET and CSF measurement of Aβ1-42, Aβ1-40, Aβ1-38, and total tau (ttau). (18)F-flutemetamol retention was quantified using standardized uptake value ratios in a composite cortical region (SUVRcomp) with reference to cerebellar grey matter. Based on a prior autopsy validation study, the SUVRcomp cut-off was 1.57. Sensitivities, specificities and cut-offs were defined based on receiver operating characteristic analysis with CSF analytes as variables of interest and (18)F-flutemetamol positivity as the classifier. We also determined sensitivities and CSF cut-off values at fixed specificities of 90 % and 95 %. Results Seven out of 38 subjects (18 %) were positive on amyloid PET. Aβ42/ttau, Aβ42/Aβ40, Aβ42/Aβ38, and Aβ42 had the highest accuracy to identify amyloid-positive subjects (area under the curve (AUC) ≥ 0.908). Aβ40 and Aβ38 had significantly lower discriminative power (AUC = 0.571). When specificity was fixed at 90 % and 95 %, Aβ42/ttau had the highest sensitivity among the different CSF markers (85.71 % and 71.43 %, respectively). Sensitivity of Aβ42 alone was significantly lower under these conditions (57.14 % and 42.86 %, respectively). Conclusion For the CSF-based definition of preclinical AD, if a high specificity is required, our data support the use of Aβ42/ttau rather than using Aβ42 in isolation.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Adamczuk, K., Schaeverbeke, J., Vanderstichele, H. M., Lilja, J., Nelissen, N., Van Laere, K., et al. (2015). Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-015-0159-5
Vancouver
Adamczuk K, Schaeverbeke J, Vanderstichele HM, Lilja J, Nelissen N, Van Laere K, et al. Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease. Alzheimer's research & therapy. 2015. doi:10.1186/s13195-015-0159-5. PMID: 26677842.
BibTeX
@article{adamczuk2015-26677842,
author = {Adamczuk, K. and Schaeverbeke, J. and Vanderstichele, H. M. and Lilja, J. and Nelissen, N. and Van Laere, K. and Dupont, P. and Hilven, K. and others},
title = {{Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease}},
journal = {Alzheimer's research \& therapy},
year = {2015},
doi = {10.1186/s13195-015-0159-5},
pmid = {26677842},
url = {https://doi.org/10.1186/s13195-015-0159-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Seven out of 38 subjects (18 %) were positive on amyloid PET.
- Aβ40 and Aβ38 had significantly lower discriminative power (AUC = 0.571).
- Sensitivity of Aβ42 alone was significantly lower under these conditions (57.14 % and 42.86 %, respectively).
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants38
- Effect sizeAUC = 0.571
- Evidence strengthLow
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 30 of the 58 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 38 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 26677842) |
| Free to read | 2 / 2 | Free to read |
| Points | 30 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 30 of the 58 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “diagnostic-value”
7 studies in the library carry the topic tag “diagnostic-value”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 7 tagged studies.